Following new analysis of comprehensive data sets from Phase III studies, Biogen has now decided to submit an application for approval for aducanumab, as detailed in a press release issued by Neurimmune. The Schlieren-based biotechnology company developed the active ingredient to combat Alzheimer’s disease in collaboration with researchers at the University of Zurich (UZH) before subsequently signing a development and licensing agreement with Biogen.
“Today's news marks a substantial advancement in neuroscience”, comments Roger Nitsch, CEO and President of Neurimmune, before adding: “This is long-awaited progress in finding a treatment for Alzheimer's disease”.
Aducanumab is an antibody which binds in targeted fashion to disease-causing cerebral amyloids in patients suffering from Alzheimer’s disease with the aim of removing these. The new analysis of the study findings has now shown that the removal of the cerebral amyloids led to a significant effect on both cognition and function, as outlined by Neurimmune in the press release. “Today, we are moving a meaningful step closer toward our joint goal of delivering a treatment for Alzheimer's disease”, Nitsch explains.
Biogen is a US biotechnology firm headquartered in Cambridge, Massachusetts. The markets outside of the USA are served by Biogen's international headquarters in Zug in the Greater Zurich Area. Moreover, the company is currently in the process of building a cutting-edge biopharmaceutical production facility in Luterbach SO. Following the announcement of this latest development on Tuesday, the company’s share price soared before opening.
Neurimmune is a spin-off affiliated with UZH headquartered in the Bio-Technopark Schlieren-Zürich.